---
title: AstraZeneca (AZN)
layout: default
nav_order: 47
---

# AstraZeneca
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $220 B

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Diseases.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=AZN+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/AZN/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat (3/5):**

AstraZeneca's moat primarily stems from its **intangible assets**, specifically its patents and brand recognition.  Patents, as discussed in Pat Dorsey's *The Little Book That Builds Wealth*, can offer strong protection, but patent lawyers are not poor.  Legal challenges are the biggest risk to a patent moat. The history of Big Pharma shows that these moats are not insurmountable and can be easily eroded once patents expire or face successful challenges (as discussed in *The Little Book that Builds Wealth*). AZN relies heavily on patent protection for key drugs and faces the ever-present threat of generic competition and biosimilars as key drugs like Tagrisso and Imfinzi lose patent protection.

{: .warning }

AstraZeneca has seen increased competition in the respiratory space, which could narrow its moat over time, as highlighted in its Q1 2023 earnings call. 
Further, as mentioned in the Morgan Stanley report on moats, the more money a firm makes, the bigger it gets, the more likely it is to face heavy competition from new entrants.

While AZN’s large size offers some benefits (scale economies in R&D, sales, and administration) and global reach, these are not exclusive and do not constitute a moat on their own, as discussed in Dorsey’s book. Its size may enable it to acquire small, innovative companies, which it has done, but the success of integration and product development to create a sustainable advantage remains to be seen. 

{: .note }

Therefore, while not a wide-moat company, AstraZeneca earns a 3 because of its current patent portfolio and strong brand recognition, but its moat is narrow and under constant pressure.


**Management (3/5):**

A key element of management quality, as highlighted in *Valuation: Measuring and Managing the Value of Companies*, is capital allocation.  AstraZeneca's history of acquisitions and divestitures has been mixed. While some have created value, others (like the $39 billion acquisition of Alexion in 2021) have been questioned for their strategic and financial rationale.  

{: .important }

As discussed in Graham's *The Intelligent Investor*, large acquisitions are often difficult to integrate and create synergies from, with acquirers overpaying for target companies and focusing on earnings-per-share accretion rather than intrinsic value creation.

Executive compensation is substantial but broadly in line with industry peers. Insider ownership appears limited, which can decrease the incentive for management to act in shareholders' best interests, as discussed in *The Essays of Warren Buffett*. Communication is adequate, with quarterly earnings calls and investor presentations, but they lack the detailed breakdowns of drivers of value that truly transparent companies offer.

{: .note }

While management appears competent, there’s no evidence of exceptional capital allocation skill or commitment to maximizing long-term shareholder value. Hence, the 3 rating.


**Catalyst (2/5):**

Potential catalysts for AstraZeneca include the development and approval of new drugs in its pipeline, especially in Oncology and Rare Diseases. As discussed in the Q1 2023 earnings call, the company has several promising drugs in late-stage development.  However, drug development is inherently risky and expensive, and FDA approval is not guaranteed, as mentioned in *The Essays of Warren Buffett*. Another potential catalyst is the successful integration of recent acquisitions, but as discussed earlier, this is a challenging and uncertain endeavor. Cost-cutting initiatives could also boost profitability, but as highlighted in *Valuation: Measuring and Managing the Value of Companies*, these are easier said than done and often overpromised.

{: .note }

Since drug development can take between seven to eleven years from laboratory to launch, the company is susceptible to unforeseen economic and political developments in the interim, as pointed out by Dorsey in *The Little Book that Builds Wealth*.

Overall, the catalyst rating is 2, reflecting moderate potential for pipeline success but acknowledging the inherent uncertainties and execution risk associated with drug development and acquisition integration.


**Business and Financials:**

AstraZeneca operates in a highly competitive industry, with other major players like Pfizer, Novartis, and Roche. The company has a strong presence in Oncology, which is the fastest growing therapeutic area, followed by Rare Diseases, as mentioned in Q2 2023 earnings call.  However, competition is intense, and the pricing power of any individual drug is limited by payers and the threat of generics and biosimilars.  AZN's growth has been fueled by both organic revenue growth and acquisitions, but as highlighted in *The Little Book that Builds Wealth*, sustaining high growth is always a challenge.  Profitability has been healthy, with double-digit operating margins and strong returns on invested capital (as noted in *The Little Book that Builds Wealth* when assessing profitability).

**Valuation ($220 billion):**

A three-stage discounted cash flow (DCF) model was used to value AstraZeneca. This aligns with the approach suggested in *Valuation: Measuring and Managing the Value of Companies* of using an explicit forecast for a number of years and then estimating a continuing value over the remaining years.  A pessimistic bias was incorporated into the valuation assumptions.


**Key Assumptions:**

* **Revenue Growth:** 5% for the next 5 years (declining from 8% current growth rate), then 3% in stable growth, given concerns about increasing competition and patent expirations, as noted in Q1 2023 earnings call. This is in line with the Morgan Stanley view in “Measuring the Moat” that company growth is always a challenge and that companies eventually stabilize.
* **Operating Margin:** 30% (in line with historical average, but recognizing potential margin compression from increasing competition and payer pressures). It is consistent with Dorsey’s view that profitability is a key driver of a company’s value.
* **Cost of Capital (WACC):** 8% (reflecting a risk-free rate of 4%, an equity risk premium of 4%, and a beta of 0.9, in line with Bloomberg and Value Line, adjusted to its target capital structure of 10% debt). Consistent with Graham’s emphasis on avoiding speculative returns in *The Intelligent Investor*.
* **Reinvestment Rate:**  Reinvests 40% of after-tax operating income (decreasing gradually to 10% in stable growth).

{: .important }

As suggested by Graham, a company should reinvest its earnings only when it can earn a rate of return on incremental capital at least equal to or higher than that generally available to its shareholders and calculated its intrinsic value on that basis. AZN’s ROIC is lower than its cost of capital.

**DCF Model:**

A simplified DCF was used, with the valuation broken down as suggested in Damodaran’s presentation *The Dark Side of Valuation*: Value of Firm = Value of Operating Assets + Value of Non-Operating Assets.

* **Value of Operating Assets:** Discounted the free cash flow to the firm for the next 10 years and terminal value, using the WACC, and summed these values.
* **Value of Non-operating Assets:** Summed the market values of excess cash (using WACC as a discount rate) and other non-operating assets.

This approach, consistent with Damodaran's framework in his presentation, yielded a value of approximately $220 billion for AstraZeneca in February 2024.



{: .note }

This valuation is sensitive to changes in assumptions, particularly revenue growth and margin. A sensitivity analysis reveals that a one-percentage-point change in the long-term growth rate has a significant impact on the valuation. This is consistent with Graham's caution about projections in *The Intelligent Investor* and emphasizes the importance of conservative assumptions when valuing companies.

**Closing Thoughts:**

While AstraZeneca has a portfolio of successful drugs and a strong pipeline, investors should be wary of the inherent risks and uncertainties associated with the pharmaceutical industry. The stock price has reflected optimistic assumptions about future growth. There's no margin of safety at the current valuation, and investors would be better off waiting for a pullback or looking for other opportunities, as advised in both *The Intelligent Investor* and *Common Stocks and Uncommon Profits*.  As suggested by Burry’s approach in *MSN Money Articles*, looking at returns over several years and thinking in terms of bond yields gives some perspective on investment decisions.